Compare CVRX & PSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CVRX | PSF |
|---|---|---|
| Founded | 2000 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 253.2M | 251.0M |
| IPO Year | 2021 | N/A |
| Metric | CVRX | PSF |
|---|---|---|
| Price | $9.77 | $20.53 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $13.17 | N/A |
| AVG Volume (30 Days) | ★ 275.1K | 25.0K |
| Earning Date | 11-05-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.69% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $55,969,000.00 | N/A |
| Revenue This Year | $11.32 | N/A |
| Revenue Next Year | $18.58 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 18.44 | N/A |
| 52 Week Low | $4.30 | $16.00 |
| 52 Week High | $18.55 | $20.19 |
| Indicator | CVRX | PSF |
|---|---|---|
| Relative Strength Index (RSI) | 54.37 | 50.55 |
| Support Level | $8.37 | $19.92 |
| Resistance Level | $10.28 | $20.36 |
| Average True Range (ATR) | 0.69 | 0.19 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 76.44 | 63.27 |
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
Cohen & Steers Select Preferred and Income Fund Inc is a diversified, closed-end investment company. The Fund's primary investment objective is high current income with capital appreciation as its secondary objective. The Fund invests at least of its Managed Assets in preferred and other income securities issued by U.S. and non-U.S. companies.